Proof of Market of an Innovative Microbial Air Sampler Hybrid (MASH)

在制药、医疗保健和食品等行业，空气微生物污染的测量是必不可少的，以确保达到立法标准。有几个案例研究表明，目前的采样器未能计算出GB M的成本，例如，辉瑞工厂被禁止向欧盟供应药物，原因是无菌工艺没有经过优化，以降低微生物污染的风险；CHIRON未能监测微生物污染，导致4800万支流感疫苗受到污染(并被召回)--占美国需求的一半。我们已经找到了一个机会来开发一种使用较小的琼脂平板的创新取样器，能够在10分钟内高效率地取样1立方米。此次POM的目的是确定市场胃口、细分市场和技术发展路径。到2019年，全球空气监测市场预计将达到61.6亿美元，我们早期的预测是市场渗透率的0.3%，相当于到第三年开发后收入为1850万美元(1390万GB)。

The measurement of microbial air contamination is essential in sectors such as pharmaceuticals, healthcare & food to ensure legislative standards are met. There are several case studies where current samplers have failed costing £M's e.g. Pfizer plant banned from supplying drugs to EU due to aseptic processes not optimised to reduce risk of microbial contamination; Chiron’s failure to monitor microbial contamination led a contamination (and withdrawal) of 48M flu vaccines – half of U.S. demand. We have identified an opportunity to develop an innovative sampler using the smaller agar plate, capable of sampling 1m3 in 10 minutes at high efficiency. The purpose of this PoM is to confirm the market appetite, segmentation and technology development path. The global market for air monitoring is expected to reach $6.16bn, by 2019, and our early projections are 0.3% of market penetration, equating to revenues of $18.5M (£13.9m) by year-3 post development.